January 29, 2021 -- Charles River Laboratories is joining forces with Cypre to advance the understanding of the tumor microenvironment and predict therapeutic efficacy. Charles River clients will have access to Cypre's 3D tumor model assay, Falcon-X, a move that expands Charles River's 3D in vitro testing services.
The Falcon-X 3D in vitro tumor assay is an analysis screening option for cancer immunotherapy and targeted therapy. Using Cypre's 3D hydrogel patterning technology Symphony and VersaGel, the assay recreates the tumor microenvironment and enables predictive screening of immuno-oncology compounds.
Charles River will have a new addition to Cypre's human oncology assay repertoire, allowing identification of therapeutics that overcome cancer immunotherapy resistance, the firms said. In addition, Cypre will be able to screen multiple therapeutic modalities alone or in combination using Charles River's genomically annotated and in vivo characterized cancer model database.
The database constitutes more than 700 tumor models, including patient-derived xenografts (PDX), cell lines, and cell line derived xenografts.